Replimune
Replimune Group, Inc. is a clinical stage biotechnology company with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx drug discovery platform is based on a potent HSV-1 backbone with added transgene payloads designed to maximize direct selective viral killing of the tumor and alters the tumor microenvironment (TME), triggering the release of tumor derived antigens to ignite a strong and durable systemic immune response across different cancers.